Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients

Medicine & Life Sciences

• Neurokinin-1 Receptor Antagonists 100%
• Osteosarcoma 70%
• Aprepitant 36%
• Neoplasm Metastasis 15%
• Substance P 13%
• Matrix Metalloproteinases 11%
• Therapeutics 11%
• Neurokinin-1 Receptors 8%
• Phase II Clinical Trials 7%
• Clinical Trials, Phase I 7%
• Drug Therapy 7%
• Matrix Metalloproteinase 2 6%
• NF-kappa B 6%
• Neuroprotection 6%
• Neoplasms 5%
• Antineoplastic Agents 5%
• Natural Killer Cells 5%
• Vascular Endothelial Growth Factor A 5%
• Cell Movement 5%
• Public Health 4%
• Cell Proliferation 4%
• Peptides 3%
• Apoptosis 3%
• Bone and Bones 3%
• Morbidity 3%
• Safety 3%
• In Vitro Techniques 2%
• Child 2%
• Genes 2%